Crohn's disease and ulcerative colitis are chronic inflammatory bowel diseases (IBDs) driven by the interleukin-23/Th17 pathway. Guselkumab, a selective interleukin-23p19 monoclonal antibody, has shown promise in phase II/III trials. This systematic review and meta-analysis aimed to synthesize its efficacy and safety v...
Z. Shahid, M. Azam, Ahila Ali et al.· European Journal of Gastroen...· 0 citations
Background Two-drug antiretroviral regimens are increasingly explored to simplify HIV-1 treatment while maintaining durable viral suppression. Doravirine combined with Islatravir (DOR/ISL) represents a novel non-integrase strand transfer inhibitor (non-INSTI) regimen. However, comprehensive synthesized evidence remains...
M. Azam, M. Azam, Muhammad Arif Khan et al.· Therapeutic Advances in Infe...· 0 citations
Overall, adverse events were mild, transient, and comparable across vaccines and most included trials reported no serious adverse events (SAEs), indicating a favorable safety profile.
Muhammad Hussain, Muhammad Hassan, Abdul Hannan et al.· Frontiers in Public Health· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.